TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange. When a viewer asks if Biogen's (BIIB) horseman has fallen off the horse, Cramer says he needs to reevaluate the company. Biogen, one of Cramer's 'Four Horsemen,' disappointed investors by lowering its full-year earnings and sales forecast because it no longer expects its multiple sclerosis drug Tecfidera to grow as expected. While he reconsiders the stock, Cramer stresses that he likes Regeneron (REGN), Celgene (CELG) and Gilead (GILD) much more than Biogen here. Another viewer notes that Inotek Pharmaceuticals (ITEK) just had a positive phase two meeting with the U.S. Food and Drug Administration and asks if the stock is a buy here. Cramer explains that the smart money was already there before the company's meeting with the FDA and that the stock would be too risky for him now. When it comes to Sprint (S), Cramer says the stock is a sell. He says it's a balance sheet issue for Sprint and he believes the company needs to raise a lot of money. He also weighs in on other names in the space like T-Mobile (TMUS), AT&T (T) and Verizon (VZ). If you have a stock question, tweet it @jimcramer using #CramerQ.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.